FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to pharmaceutical chemistry and includes a macrocyclic compound of formula (II), pharmaceutically acceptable salts thereof, a pharmaceutical composition based thereon, use and a method of treatment. In formula (II) R3m is selected from
G1 is independently selected from -CH 2 - or 
; ring A is 
; each of R2a, R2b, R2c and R2d is independently selected from hydrogen and C1-C3 alkyl.
EFFECT: macrocyclic compound of formula (II) used to treat a disease or condition in which STING activation has a beneficial effect.
12 cl, 13 dwg, 6 tbl, 60 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PYRAZOLE DERIVATIVE SUITABLE AS PI3K INHIBITOR | 2016 |
|
RU2710549C2 |
| HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | 2018 |
|
RU2797822C2 |
| BICYCLIC LACTAMS AND METHODS FOR USE THEREOF | 2016 |
|
RU2716136C2 |
| HYDROXYPURINE COMPOUNDS AND USE THEREOF | 2016 |
|
RU2685417C1 |
| INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/β-CATENIN SIGNAL INHIBITORS | 2012 |
|
RU2627693C2 |
| GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | 2014 |
|
RU2664533C2 |
| APOPTOSIS INDUCING AGENTS FOR TREATING CANCER, IMMUNE AND AUTOIMMUNE DISEASES | 2011 |
|
RU2568611C2 |
| METHOD OF PRODUCING A DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIATE THEREOF | 2014 |
|
RU2719480C2 |
| HYDROXYPURINE COMPOUNDS AND WAYS OF THEIR USE | 2015 |
|
RU2673458C1 |
| CALPAIN MODULATORS AND THEIR THERAPEUTIC USE | 2017 |
|
RU2773288C2 |
